Biomerieux SA is committed to upholding strong values and a distinct corporate philosophy. The company prioritizes innovation, aiming to develop and provide cutting-edge solutions in the field of in vitro diagnostics. With a focus on healthcare, Biomerieux SA values quality, excellence, and patient well-being. By leveraging their expertise in microbiology, the company strives to improve public health worldwide. Biomerieux SA also emphasizes collaboration, teamwork, and ethical conduct among its employees. With a dedication to sustainable growth and a global outlook, Biomerieux SA continues to contribute to the advancement of diagnostic testing and improving patient outcomes.

Biomerieux SA is primarily present in countries and regions worldwide. With its global presence, Biomerieux has established a strong presence in numerous countries, including but not limited to, France, the United States, China, Brazil, India, and Japan. The company's operations span across these regions, allowing it to deliver its innovative diagnostic solutions and laboratory services to healthcare institutions, research facilities, and other related entities. Biomerieux's commitment to expanding its network ensures that its products and expertise are accessible to diverse populations, ultimately contributing to improved healthcare outcomes globally.

Biomerieux SA has achieved significant milestones throughout its history. The company has successfully developed and launched innovative diagnostic solutions for various diseases and conditions, contributing to improved patient care worldwide. Biomerieux SA also expanded its global presence by establishing strategic partnerships and acquiring complementary businesses. With a strong focus on research and development, the company has received numerous regulatory approvals for its diagnostic tests and devices. In addition, Biomerieux SA has garnered recognition for its commitment to sustainability and corporate social responsibility initiatives. These notable achievements highlight Biomerieux SA's dedication to advancing healthcare technology and delivering reliable diagnostic solutions.

Biomerieux SA, a leading global player in the field of in vitro diagnostics, has a rich history and background. The company was founded in 1963 by Dr. Alain Merieux with a vision to improve public health and patient care. Over the years, Biomerieux has expanded its portfolio and expertise in microbiology, infectious diseases, and molecular diagnostics. With a strong commitment to innovation, the company has developed pioneering diagnostic solutions, including automated systems and reagents. Biomerieux serves various industries, including clinical laboratories, food testing, and pharmaceuticals, enabling timely and accurate disease detection and better treatment outcomes. With continuous research and development efforts, Biomerieux remains at the forefront of diagnostic solutions globally.

The main competitors of Biomerieux SA in the market include companies like Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, and QIAGEN N.V.

Biomerieux SA is primarily active in the diagnostics industry.

The business model of Biomerieux SA is focused on diagnostic solutions for infectious diseases and cancer. The company develops and manufactures in vitro diagnostic tests, instruments, and software that aid in detecting diseases and guiding patient treatment. Biomerieux's comprehensive portfolio caters to clinical laboratories, hospitals, and industrial microbiology laboratories globally. Their solutions include microbiology, immunoassays, molecular biology, and blood culture systems. By leveraging cutting-edge technologies, Biomerieux aims to improve patient outcomes and enhance public health through early and accurate diagnosis. With a strong emphasis on research and innovation, the company continues to lead in the field of clinical diagnostics, offering reliable and efficient solutions for healthcare professionals worldwide.

The Biomerieux P/E ratio is 23.39.

The Biomerieux P/S ratio is 2.98.

The Quality Investing for Biomerieux is 7/10.

The expected Biomerieux revenue is 4.29 B EUR.

The expected Biomerieux profit is 547.11 M EUR.

The company Biomerieux SA was founded in 1963 and is headquartered in France. It is a leading manufacturer of in vitro diagnostics (IVD) and specializes in the development and production of solutions for the diagnosis of infectious diseases. Biomerieux operates several subsidiaries worldwide and employs approximately 12,000 people. Biomerieux's business model includes several divisions, including clinical diagnostics, industrial microbiology, food and water diagnostics, and veterinary diagnostics. In clinical diagnostics, the company offers a wide range of solutions for the diagnosis of infectious diseases. This includes test kits for the identification of bacteria, viruses, and fungi, PCR tests, and microbiology systems for determining antibiotic susceptibility. In industrial microbiology, Biomerieux specializes in the development of systems for the rapid identification of microorganisms in the food and beverage industry. The company also provides solutions for water quality control and industrial processes. The tests range from detecting contaminants in water samples to monitoring cleanroom conditions in the pharmaceutical industry. In the field of food and water diagnostics, Biomerieux is a global leader in the development of innovative solutions for detecting foodborne infections and toxins. The company offers a wide range of tests for monitoring food and drinking water. This also includes tests for controlling milk cultures and their fermentation. Veterinary diagnostics is another important area for Biomerieux. The company has developed a range of test kits for the diagnosis of animal diseases, including tests for the detection of infectious diseases in livestock. Biomerieux has become a key player in the field of medical diagnostics. The company invests heavily in research and development to develop new solutions for the diagnosis of infectious diseases. In addition, Biomerieux places great value on collaboration with other companies and research institutions to further improve the field of medical diagnostics. Overall, Biomerieux SA offers a wide range of solutions for the diagnosis of infectious diseases. The company is a leader in the fields of clinical diagnostics, industrial microbiology, food and water diagnostics, and veterinary diagnostics. Biomerieux continues to invest in research and development to develop innovative solutions that further improve the diagnosis of infectious diseases.

Biomerieux pays a dividend of 0.85 EUR distributed over payouts per year.

The dividend cannot currently be calculated for Biomerieux or the company does not pay out a dividend.

The ISIN of Biomerieux is FR0013280286.

The WKN of Biomerieux is A2DXZH.

The ticker of Biomerieux is BIM.PA.

Over the past 12 months, Biomerieux paid a dividend of 0.85 EUR . This corresponds to a dividend yield of about 0.79 %. For the coming 12 months, Biomerieux is expected to pay a dividend of 0.94 EUR.

The current dividend yield of Biomerieux is 0.79 %.

Biomerieux pays a quarterly dividend. This is distributed in the months of July, July, July, July.

Biomerieux paid dividends every year for the past 24 years.

For the upcoming 12 months, dividends amounting to 0.94 EUR are expected. This corresponds to a dividend yield of 0.87 %.

Biomerieux is assigned to the 'Health' sector.

To receive the latest dividend of Biomerieux from 6/11/2024 amounting to 0.85 EUR, you needed to have the stock in your portfolio before the ex-date on 6/7/2024.

The last dividend was paid out on 6/11/2024.

In the year 2024, Biomerieux distributed 0.85 EUR as dividends.

The dividends of Biomerieux are distributed in EUR.